Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYCS | P99999 | 4/20 | 0.78 |
| ▸ | TOP1 | P11387 | 4/20 | 0.77 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556585 | 0.89 | TOP1 (0.91) | CYCSTOP1ENPP2ABCG2KDM4E | |
| SCHEMBL16418477 | 0.89 | TOP1 (0.91) | CYCSTOP1ENPP2ABCG2KDM4E | |
| SCHEMBL25395869 | 0.89 | TOP1 (0.91) | CYCSTOP1ENPP2ABCG2KDM4E | |
| SCHEMBL25394852 | 0.89 | TOP1 (0.91) | CYCSTOP1ENPP2ABCG2KDM4E | |
| SCHEMBL483511 | 0.89 | TOP1 (0.91) | CYCSTOP1ENPP2ABCG2KDM4E | |
| SCHEMBL12842181 | 0.89 | CYCS (0.97) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL6686149 | 0.88 | TOP1 (0.88) | CYCSTOP1ENPP2ABCG2KDM4E | |
| SCHEMBL6693557 | 0.88 | TOP1 (0.88) | CYCSTOP1ENPP2ABCG2KDM4E | |
| SCHEMBL29520928 | 0.88 | TOP1 (0.88) | CYCSTOP1ENPP2ABCG2KDM4E | |
| SCHEMBL19640818 | 0.88 | CYCS (0.91) | CYCSTOP1ENPP2ABCG2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114177197-A | Use of vanadium compounds for maintaining normoglycemia in a mammal | CFM医药控股有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20220040195-A1 | USE OF VANADIUM COMPOUNDS FOR MAINTAINING NORMAGLYCEMIA IN A MAMMAL | CFM PHARMA HOLDING BV (NL) | 2022-02-10 | — | — | US | disclosed |
| CN-107088202-B | Use of vanadium compounds for maintaining normoglycemia in a mammal | CFM医药控股有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-11179401-B2 | Use of vanadium compounds for maintaining normaglycemia in a mammal | CFM PHARMA HOLDING BV (NL) | 2021-11-23 | — | — | US | disclosed |
| US-20200078372-A1 | USE OF VANADIUM COMPOUNDS FOR MAINTAINING NORMAGLYCEMIA IN A MAMMAL | CFM PHARMA HOLDING BV (NL) | 2020-03-12 | — | — | US | disclosed |
| US-10449204-B2 | Use of vanadium compounds for maintaining normaglycemia in a mammal | CFM PHARMA HOLDING BV (NL) | 2019-10-22 | — | — | US | disclosed |
| EP-2683374-B1 | USE OF VANADIUM COMPOUNDS FOR MAINTAINING NORMAGLYCEMIA IN A MAMMAL | CFM PHARMA HOLDING BV (NL) | 2019-09-25 | — | — | EP | disclosed |
| US-20140072647-A1 | USE OF VANADIUM COMPOUNDS FOR MAINTAINING NORMAGLYCEMIA IN A MAMMAL | CFM PHARMA HOLDING BV | 2014-03-13 | — | — | US | disclosed |
| EP-2683374-A1 | USE OF VANADIUM COMPOUNDS FOR MAINTAINING NORMAGLYCEMIA IN A MAMMAL | CFM Pharma Holding BV (NL) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012121596-A1 | USE OF VANADIUM COMPOUNDS FOR MAINTAINING NORMAGLYCEMIA IN A MAMMAL | CFM PHARMA HOLDING BV (NL) | 2012-09-13 | — | — | WO | disclosed |